Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Comment: Advances in breast cancer presented at ASCO 2014

Comment: Advances in lung cancer presented at ASCO 2014

Ramucirumab plus docetaxel extends survival in advanced NSCLC

Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Emerging pathways in immunotherapy

Checkpoint blockade: a concept or already a reality?